![Sin imagen](https://static.cymitquimica.com/public/img/logo-cymit-gray.png)
CAS: 1951431-22-3
Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
---|---|---|---|---|
![]() | BKI-1369 REF: 3D-BDD43122CAS: 1951431-22-3 | Min. 95% | A consultar | Lun 12 Ago 24 |
![]() | BKI-1369 REF: TM-T10556CAS: 1951431-22-3 | - - - | 158,00 €~2.340,00 € | Lun 19 Ago 24 |
![discount label](https://static.cymitquimica.com/public/img/discount.png)
BKI-1369
CAS:1951431-22-3
BKI-1369 is an experimental drug in the class of benzimidazole derivatives that is being studied …
Fórmula:
C23H27N7O
Pureza:
Min. 95%
Peso molecular:
417.51 g/mol
Ref: 3D-BDD43122
1mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Entrega estimada en Estados Unidos, el Lunes 12 de Agosto de 2024
![discount label](https://static.cymitquimica.com/public/img/discount.png)
BKI-1369
CAS:1951431-22-3
BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
Fórmula:
C23H27N7O
Peso molecular:
417.51
Ref: TM-T10556
5mg | 444,00 € | ||
25mg | 1.410,00 € | ||
50mg | 1.854,00 € | ||
100mg | 2.340,00 € |
Entrega estimada en Estados Unidos, el Lunes 19 de Agosto de 2024